AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate bretisilocin (GM-2505), a next-generation psychedelic compound in Phase 2 development for major depressive disorder (MDD). The $1.2 billion transaction underscores AbbVie’s growing commitment to neuroscience and expands its psychiatry pipeline with a potential best-in-class therapy designed to address unmet needs in treatment-resistant depression.
Science Significance
Bretisilocin is a novel, short-acting 5-HT2A receptor agonist and 5-HT releaser engineered to deliver rapid antidepressant effects with a shorter psychoactive experience compared to classical psychedelics. Phase 2a results showed a -21.6 point reduction in MADRS score after a single 10 mg dose, demonstrating both statistical significance (p=0.003) and clinical impact versus active comparator. Importantly, the therapy was well tolerated with no serious adverse events, signaling promise for a safer, more practical psychedelic-based antidepressant.
Regulatory Significance
The acquisition accelerates AbbVie’s pathway to late-stage development and regulatory engagement with the FDA and global authorities. Given the fast-evolving regulatory landscape for psychedelic medicines, bretisilocin could become a test case for how agencies evaluate short-acting psychedelic compounds with differentiated benefit-risk profiles. The clean safety data and reduced duration of psychoactive effects may simplify regulatory review relative to first-generation psychedelic agents.
Business Significance
Advertisement
Valued up to $1.2 billion in upfront and milestone payments, the deal highlights the increasing investor and Big Pharma confidence in psychedelic-inspired therapeutics. AbbVie secures exclusive rights to a lead asset while Gilgamesh spins out Gilgamesh Pharma Inc., retaining its team and broader pipeline, including:
M1/M4 muscarinic agonist discovery portfolio
This transaction builds on the 2024 AbbVie-Gilgamesh collaboration, preserving AbbVie’s option-to-license agreement, which will now be managed by Gilgamesh Pharma Inc.
Blixeprodil (GM-1020): Oral NMDA receptor antagonist in Phase 2a for MDD
Cardio-safe ibogaine analog program
Patients’ Significance
With nearly 300 million people worldwide affected by depression and many experiencing inadequate response to existing therapies, the need for rapid, durable, and tolerable treatments is critical. Bretisilocin’s fast onset and shorter psychoactive window may lower barriers to adoption by patients, caregivers, and clinicians, potentially improving treatment accessibility while reducing clinical supervision burdens compared to longer-acting psychedelics.
Policy Significance
The transaction further validates psychedelics as a mainstream therapeutic class in psychiatry. As governments, payers, and regulators debate policies on reimbursement and controlled-substance scheduling, AbbVie’s entry could catalyze new policy frameworks for psychedelic-derived medicines. The deal signals industry confidence that policy alignment on medical psychedelics is accelerating globally.
Transaction Highlights
Acquirer: AbbVie (NYSE: ABBV)
Seller: Gilgamesh Pharmaceuticals
Asset: Bretisilocin (GM-2505), Phase 2 psychedelic therapy for MDD
Deal Value: Up to $1.2 billion (upfront + milestones)
Structure: AbbVie acquires bretisilocin program; Gilgamesh spins out new entity Gilgamesh Pharma Inc.
Pipeline Retained by Gilgamesh Pharma Inc.: Blixeprodil (GM-1020), ibogaine analog, M1/M4 agonists, AbbVie collaboration
Advisors: Covington & Burling LLP (AbbVie legal), Centerview Partners LLC (Gilgamesh financial), Ropes & Gray LLP (Gilgamesh legal)
Source: AbbVie Press Release
